Valuation: Harrow, Inc.

Market Cap 1.49B 1.29B 1.21B 1.11B 2.09B 142B 2.12B 14.15B 5.55B 70.82B 5.59B 5.47B 236B P/E 2026 *
172x
P/E 2027 * 17.1x
Enterprise Value 1.49B 1.29B 1.21B 1.11B 2.09B 142B 2.12B 14.15B 5.55B 70.82B 5.59B 5.47B 236B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 2.88x
Free-Float
84.53%
Yield 2026 *
-
Yield 2027 * -
1 day+1.29%
1 week+2.52%
Current month+2.97%
1 month-11.15%
3 months-0.87%
6 months-15.64%
Current year-18.53%
1 week 38
Extreme 38
40.64
1 month 36.25
Extreme 36.25
47.5
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 2011-12-16
President 43 2025-08-20
Compliance Officer - 2023-09-30
Director TitleAgeSince
Chairman 53 2021-08-18
Director/Board Member 57 2022-03-30
Director/Board Member 71 2024-01-25
Date Insider Type Main position Quantity % Market Cap.
2/27/26
Opaleye Management, Inc.
SellCompany 5,000 0.0135%
1/30/26 Free

CHIEF COMMERCIAL OFFICER

40,000 0.1080%
1/30/26 Other

CHIEF COMMERCIAL OFFICER

30,000 0.0810%
Change 5-day change 1-year change 3-year change Capi.($)
+1.29%+2.52%+20.90%+91.74% 1.47B
+1.89%+3.20%+59.70%+165.18% 1,043B
-0.24%+0.45%+50.64%+52.02% 621B
-0.95%-5.26%+24.23%+65.08% 435B
0.00%+3.20%+46.70%+37.60% 361B
+0.58%-1.26%+35.52%+40.54% 293B
-1.55%-6.84%+7.20%+8.62% 251B
-0.73%+4.44%+42.22%+66.41% 220B
-0.24%-11.27%+1.42%-44.69% 201B
-0.68%-0.32%+18.66%+66.32% 164B
Average -0.34%-2.14%+30.72%+54.88% 359.06B
Weighted average by Cap. -0.54%-1.42%+40.66%+77.19%

Financials

2026 *2027 *
Net sales 348M 302M 283M 259M 489M 33.19B 495M 3.31B 1.3B 16.59B 1.31B 1.28B 55.2B 517M 449M 420M 385M 726M 49.29B 736M 4.92B 1.93B 24.63B 1.94B 1.9B 81.97B
Net income 9.18M 7.97M 7.46M 6.82M 12.88M 875M 13.05M 87.28M 34.25M 437M 34.47M 33.72M 1.45B 93.99M 81.56M 76.37M 69.86M 132M 8.95B 134M 893M 351M 4.47B 353M 345M 14.89B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
26-08-06 US$39.92 +1.29% 333,239
26-08-05 US$39.41 -1.05% 301,807
26-08-04 US$39.83 +1.89% 368,338
26-08-03 US$39.09 +0.83% 400,523
26-07-31 US$38.77 -0.44% 261,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
39.92USD
Average target price
67.75USD
Spread / Average Target
+69.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock